Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

New treatments are needed for B-cell malignancies persisting after allogeneic hematopoietic stem cell transplantation (alloHSCT). We conducted a clinical trial of allogeneic T cells genetically modified to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19. T cells for genet...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Kochenderfer, James N., Dudley, Mark E., Carpenter, Robert O., Kassim, Sadik H., Rose, Jeremy J., Telford, William G., Hakim, Frances T., Halverson, David C., Fowler, Daniel H., Hardy, Nancy M., Mato, Anthony R., Hickstein, Dennis D., Gea-Banacloche, Juan C., Pavletic, Steven Z., Sportes, Claude, Maric, Irina, Feldman, Steven A., Hansen, Brenna G., Wilder, Jennifer S., Blacklock-Schuver, Bazetta, Jena, Bipulendu, Bishop, Michael R., Gress, Ronald E., Rosenberg, Steven A.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2013
נושאים:
Transplantation
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3862276/
https://ncbi.nlm.nih.gov/pubmed/24055823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-08-519413
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים